Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
On June 24, 2024, Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo). The two parties will engage in comprehensive and in-depth collaboration in multiple fields, including animal electrocardiogram diagnostics and personnel training, as well as animal ophthalmic disease diagnosis and model establishment, to jointly promote the development of innovative drugs. Complementary advantages drive improvement; working together to empower new capabilities Supporting the development of cardiovascular and ophthalmic disease drugs Hetuo is a CRO specializing in preclinical pharmacodynamic evaluation, focusing on translational medicine platform technologies, and actively promoting the industrialization of medicine. The company adheres to GLP standards, implementing scientific management of projects to ensure the authenticity, accuracy/scientific integri...